$NTRA
Natera, Inc.

2024 Q1 Form 10-K Financial Statement

#000155837024002083 Filed on February 29, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $367.7M $311.1M $1.083B
YoY Change 52.11% 43.2% 31.99%
Cost Of Revenue $159.1M $151.2M $589.8M
YoY Change 7.44% 18.82% 29.28%
Gross Profit $208.6M $159.9M $492.7M
YoY Change 122.79% 77.7% 35.38%
Gross Profit Margin 56.72% 51.38% 45.52%
Selling, General & Admin $194.3M $161.4M $618.3M
YoY Change 29.84% 12.24% 5.05%
% of Gross Profit 93.13% 100.98% 125.48%
Research & Development $88.64M $82.96M $320.7M
YoY Change 7.69% -5.63% 1.35%
% of Gross Profit 42.49% 51.9% 65.08%
Depreciation & Amortization $7.063M $6.911M $24.10M
YoY Change 39.12% 75.85% 44.28%
% of Gross Profit 3.39% 4.32% 4.89%
Operating Expenses $282.9M $244.4M $939.0M
YoY Change 21.98% 5.46% 3.75%
Operating Profit -$74.31M -$84.54M -$446.2M
YoY Change -46.27% -40.37% -17.52%
Interest Expense $3.124M $6.696M $12.64M
YoY Change 2.06% -343.31% 35.62%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$67.17M -$77.84M -$434.5M
YoY Change -50.89% -45.24% -20.54%
Income Tax $428.0K $191.0K $300.0K
% Of Pretax Income
Net Earnings -$67.60M -$78.03M -$434.8M
YoY Change -50.62% -45.27% -20.63%
Net Earnings / Revenue -18.38% -25.08% -40.16%
Basic Earnings Per Share -$0.56 -$3.78
Diluted Earnings Per Share -$0.56 -$0.65 -$3.78
COMMON SHARES
Basic Shares Outstanding 120.8M 120.2M 115.0M
Diluted Shares Outstanding 120.8M 115.0M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $882.9M $879.0M $879.0M
YoY Change 8.73% -2.15% -2.15%
Cash & Equivalents $813.8M $642.1M $642.1M
Short-Term Investments $69.12M $236.9M $236.9M
Other Short-Term Assets $46.73M $60.52M $60.52M
YoY Change 55.84% 79.49% 79.49%
Inventory $43.02M $40.76M $40.76M
Prepaid Expenses
Receivables $288.7M $278.3M $278.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.261B $1.259B $1.259B
YoY Change 11.68% 3.86% 3.86%
LONG-TERM ASSETS
Property, Plant & Equipment $125.8M $111.2M $167.7M
YoY Change 25.06% 20.29% 2.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.42M $15.40M $15.40M
YoY Change 36.96% -15.97% -15.97%
Total Long-Term Assets $206.8M $183.2M $183.2M
YoY Change 9.16% 0.27% 0.27%
TOTAL ASSETS
Total Short-Term Assets $1.261B $1.259B $1.259B
Total Long-Term Assets $206.8M $183.2M $183.2M
Total Assets $1.468B $1.442B $1.442B
YoY Change 11.32% 3.39% 3.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $26.04M $15.00M $15.00M
YoY Change -27.92% -51.85% -51.85%
Accrued Expenses $163.8M $172.0M $172.0M
YoY Change 14.06% 1.62% 1.62%
Deferred Revenue $17.71M $16.61M
YoY Change 6.79% 54.14%
Short-Term Debt $80.40M $80.40M $80.40M
YoY Change 0.0% 0.0% 0.06%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $305.9M $307.3M $307.3M
YoY Change 5.15% -1.04% -1.04%
LONG-TERM LIABILITIES
Long-Term Debt $283.3M $282.9M $282.9M
YoY Change 0.46% 0.46% 0.46%
Other Long-Term Liabilities $84.87M $86.15M $86.15M
YoY Change -11.0% -10.79% -10.79%
Total Long-Term Liabilities $368.1M $369.1M $369.1M
YoY Change -2.44% -2.41% -2.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $305.9M $307.3M $307.3M
Total Long-Term Liabilities $368.1M $369.1M $369.1M
Total Liabilities $674.1M $676.4M $676.4M
YoY Change 0.87% -1.79% -1.79%
SHAREHOLDERS EQUITY
Retained Earnings -$2.400B -$2.400B
YoY Change 14.29% 26.32%
Common Stock $3.241B $3.146B
YoY Change 18.21% 18.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $794.1M $765.3M $765.3M
YoY Change
Total Liabilities & Shareholders Equity $1.468B $1.442B $1.442B
YoY Change 11.32% 3.39% 3.39%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$67.60M -$78.03M -$434.8M
YoY Change -50.62% -45.27% -20.63%
Depreciation, Depletion And Amortization $7.063M $6.911M $24.10M
YoY Change 39.12% 75.85% 44.28%
Cash From Operating Activities $27.00M -$58.13M -$247.0M
YoY Change -133.38% -28.35% -42.77%
INVESTING ACTIVITIES
Capital Expenditures $20.32M $9.532M $39.20M
YoY Change 75.16% -19.4% -17.82%
Acquisitions
YoY Change
Other Investing Activities $169.1M $34.20M $207.7M
YoY Change 520.42% 1.34% -45.06%
Cash From Investing Activities $138.3M $24.66M $168.5M
YoY Change 783.31% 12.54% -48.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.466M 6.845M 254.5M
YoY Change 181.01% -98.54% -47.28%
NET CHANGE
Cash From Operating Activities 27.00M -58.13M -247.0M
Cash From Investing Activities 138.3M 24.66M 168.5M
Cash From Financing Activities 6.466M 6.845M 254.5M
Net Change In Cash 171.7M -26.62M 176.0M
YoY Change -372.85% -106.51% -53.86%
FREE CASH FLOW
Cash From Operating Activities $27.00M -$58.13M -$247.0M
Capital Expenditures $20.32M $9.532M $39.20M
Free Cash Flow $6.686M -$67.66M -$286.2M
YoY Change -107.23% -27.21% -40.28%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.57
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.21
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114997000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98408000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
90558000
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111255000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119581000
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001604821
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M8D
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
119581000
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-37478
CY2023 dei Entity Registrant Name
EntityRegistrantName
NATERA, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
CY2023 dei City Area Code
CityAreaCode
650
CY2023 dei Local Phone Number
LocalPhoneNumber
980-9190
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
NTRA
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
5260000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
120757877
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Mateo, California
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236882000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
432301000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6481000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3830000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q4 us-gaap Inventory Net
InventoryNet
40759000
CY2022Q4 us-gaap Inventory Net
InventoryNet
35406000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
60524000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33634000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
1258549000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1211817000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
56537000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71874000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15403000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18330000
CY2023Q4 us-gaap Assets
Assets
1441699000
CY2022Q4 us-gaap Assets
Assets
1394474000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14998000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31148000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45857000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
44010000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80402000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80350000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
307274000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
310499000
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
282945000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
281653000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19128000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q4 us-gaap Liabilities
Liabilities
676372000
CY2022Q4 us-gaap Liabilities
Liabilities
688730000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119581000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111255000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3145837000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2664730000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2377436000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1942635000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1441699000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1394474000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1082571000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
820222000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
625486000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
320678000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
316415000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
264208000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
618307000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
588591000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
511034000
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
1528816000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
1361262000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
1093660000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-446245000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-541040000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-468174000
CY2023 us-gaap Interest Expense
InterestExpense
12638000
CY2022 us-gaap Interest Expense
InterestExpense
9319000
CY2021 us-gaap Interest Expense
InterestExpense
8305000
CY2023 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
24353000
CY2022 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3538000
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
5381000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-434530000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-546821000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-471098000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
271000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
978000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
618000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-434801000
CY2023 ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
2679000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-547799000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-471716000
CY2023 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
13277000
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-14075000
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-6546000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-421524000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-561874000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-478262000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.57
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.21
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114997000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98408000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
90558000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
486236000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11816000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13550000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
115219000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-6546000
CY2021 ntra Cumulative Effect Of New Accounting Principle In Period Of Adoption Duration
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoptionDuration
-76678000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
550822000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
30601000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-471716000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
653304000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6411000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
13037000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
152384000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-14075000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
433192000
CY2022 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
9290000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-547799000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3892000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
15128000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19774000
CY2023 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
235441000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
192437000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
13277000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-434801000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
765327000
CY2023 us-gaap Profit Loss
ProfitLoss
-434801000
CY2022 us-gaap Profit Loss
ProfitLoss
-547799000
CY2021 us-gaap Profit Loss
ProfitLoss
-471716000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
24097000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16702000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11254000
CY2022 ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
9290000
CY2021 ntra Expensed In Process Research And Development
ExpensedInProcessResearchAndDevelopment
35604000
CY2023 us-gaap Operating Lease Cost
OperatingLeaseCost
14519000
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
13770000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
10926000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
191808000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
152384000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
115219000
CY2023 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
1087000
CY2022 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
4837000
CY2021 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
7814000
CY2022 us-gaap Gain Loss On Investments
GainLossOnInvestments
-906000
CY2021 us-gaap Gain Loss On Investments
GainLossOnInvestments
46000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11000
CY2023 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1292000
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1259000
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1227000
CY2023 ntra Non Cash Interest Expense
NonCashInterestExpense
52000
CY2022 ntra Non Cash Interest Expense
NonCashInterestExpense
302000
CY2021 ntra Non Cash Interest Expense
NonCashInterestExpense
94000
CY2023 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33904000
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
122311000
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
43509000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5353000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8497000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6878000
CY2023 ntra Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
8354000
CY2022 ntra Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
622000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
26072000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1202000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3182000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-15458000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5462000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
19222000
CY2023 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
21619000
CY2022 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3069000
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
10569000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12448000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9999000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-10296000
CY2023 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
10347000
CY2022 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
47650000
CY2021 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
32682000
CY2023 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
4962000
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
2056000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-44209000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-246955000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-431501000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-335236000
CY2023 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
98303000
CY2022 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
86947000
CY2021 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
876095000
CY2022 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
248482000
CY2021 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
187580000
CY2023 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
306000000
CY2022 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
216500000
CY2021 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
532910000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39199000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47697000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41030000
CY2021 ntra Payments To Acquire Assets
PaymentsToAcquireAssets
8558000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
168498000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
330338000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-205193000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3892000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6411000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11816000
CY2023 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
15128000
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
13037000
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
13550000
CY2023 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
235441000
CY2022 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
433192000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
550822000
CY2022 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
254461000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
482640000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
576188000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
176004000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
381477000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
35759000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84614000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48855000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642095000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84614000
CY2023 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
295000
CY2022 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
549000
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
283000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
11346000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
8060000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
7077000
CY2023 ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
1582000
CY2023 ntra Net Additions To Inventory Reserve
NetAdditionsToInventoryReserve
2299000
CY2023Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
872000
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
748000
CY2022 ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
-1940000
CY2021 ntra Purchases Of Property And Equipment In Accounts Payable And Accruals
PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals
5173000
CY2023 us-gaap Stock Issued1
StockIssued1
14435000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19774000
CY2023 ntra Stock Based Compensation Included In Capitalized Software Development Costs
StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts
629000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-434800000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2400000000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
642100000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
236900000
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80400000
CY2023Q4 us-gaap Debt Instrument Collateral Amount
DebtInstrumentCollateralAmount
150000000.0
CY2023Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
20000000.0
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
55
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235800000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13144500
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
35
CY2022Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
500000
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
433200000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5175000
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
113
CY2021Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
551200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span>The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p>
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
748000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
988000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
2175000
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
240000
CY2023Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
8700000
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
5900000
CY2023 us-gaap Advertising Expense
AdvertisingExpense
1100000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2287000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3085000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2022 us-gaap Advertising Expense
AdvertisingExpense
1800000
CY2021 us-gaap Advertising Expense
AdvertisingExpense
2200000
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, and restricted cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the years ended December 31, 2023, 2022, and 2021, there were no customers exceeding 10% of total revenues on an individual basis. As of December 31, 2023 and 2022, there were no customers with an outstanding balance exceeding 10% of net accounts receivable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">For the years ended December 2023, 2022, and 2021, approximately 12.8%, 11.2%, and 5.1%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. For the years ended December 2023 and 2022, approximately 13.9% and 14.1%, respectively, of accounts receivable expected to be paid by Medicare on behalf of multiple customers.</p>
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16612000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
19128000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1082571000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
820222000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
625486000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1082571000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
820222000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
625486000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
278289000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28722000
CY2023 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
35573000
CY2022 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
28978000
CY2023 ntra Contract With Customer Liability Noncurrent Reclassification To Current
ContractWithCustomerLiabilityNoncurrentReclassificationToCurrent
-522000
CY2022 ntra Contract With Customer Liability Noncurrent Reclassification To Current
ContractWithCustomerLiabilityNoncurrentReclassificationToCurrent
-337000
CY2023 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-10564000
CY2022 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-8782000
CY2023 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-19525000
CY2022 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-17803000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
35740000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2023 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-10600000
CY2023 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
19500000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
248500000
CY2022 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-900000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
19
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
0
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
115372000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
2745000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
216548000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
215095000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
23065000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
21787000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
239613000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
236882000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3830000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2429000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
4220000
CY2023 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
2645000
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1770000
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-156000
CY2023 ntra Increase Decrease In Allowance For Doubtful Accounts Write Offs
IncreaseDecreaseInAllowanceForDoubtfulAccountsWriteOffs
-6000
CY2022 ntra Increase Decrease In Allowance For Doubtful Accounts Write Offs
IncreaseDecreaseInAllowanceForDoubtfulAccountsWriteOffs
369000
CY2021 ntra Increase Decrease In Allowance For Doubtful Accounts Write Offs
IncreaseDecreaseInAllowanceForDoubtfulAccountsWriteOffs
1635000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
6481000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
3830000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2429000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
167503000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
128151000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
56293000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35698000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
111210000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
CY2023 us-gaap Depreciation
Depreciation
22700000
CY2022 us-gaap Depreciation
Depreciation
16700000
CY2021 us-gaap Depreciation
Depreciation
11300000
CY2023Q4 ntra Cloud Based Implementation Costs
CloudBasedImplementationCosts
5500000
CY2022Q4 ntra Cloud Based Implementation Costs
CloudBasedImplementationCosts
4700000
CY2021Q4 ntra Cloud Based Implementation Costs
CloudBasedImplementationCosts
3500000
CY2023Q4 ntra Cloud Based Implementation Costs Accumulated Amortization
CloudBasedImplementationCostsAccumulatedAmortization
2500000
CY2022Q4 ntra Cloud Based Implementation Costs Accumulated Amortization
CloudBasedImplementationCostsAccumulatedAmortization
900000
CY2021Q4 ntra Cloud Based Implementation Costs Accumulated Amortization
CloudBasedImplementationCostsAccumulatedAmortization
1500000
CY2023Q4 ntra Cloud Based Implementation Costs Net Book Value
CloudBasedImplementationCostsNetBookValue
3000000.0
CY2022Q4 ntra Cloud Based Implementation Costs Net Book Value
CloudBasedImplementationCostsNetBookValue
3800000
CY2021Q4 ntra Cloud Based Implementation Costs Net Book Value
CloudBasedImplementationCostsNetBookValue
2100000
CY2023Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
3121000
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2930000
CY2023Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
10522000
CY2022Q4 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
11821000
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
24651000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
20426000
CY2023Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
7563000
CY2022Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
8833000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
45857000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
44010000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2023Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
14823000
CY2022Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
17036000
CY2023Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
11229000
CY2022Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
13281000
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10085000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
8943000
CY2023Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
43897000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
36710000
CY2023Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
3646000
CY2022Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
485000
CY2023Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
3731000
CY2022Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
4319000
CY2023Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
7111000
CY2022Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
6631000
CY2023Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
12126000
CY2022Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
23301000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
4316000
CY2022Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1821000
CY2023Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2022Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2023Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
2497000
CY2022Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
4022000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
149405000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17210000
CY2023 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
14974000
CY2022 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
23717000
CY2023 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1583000
CY2022 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1800000
CY2023 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
9094000
CY2022 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
20179000
CY2023Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
23245000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2023 ntra Noncash Activities Related To Right Of Use Assets
NoncashActivitiesRelatedToRightOfUseAssets
2100000
CY2022 ntra Noncash Activities Related To Right Of Use Assets
NoncashActivitiesRelatedToRightOfUseAssets
22100000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11621000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
67025000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
78646000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
84216000
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.068
CY2023 us-gaap Lease Cost
LeaseCost
14500000
CY2022 us-gaap Lease Cost
LeaseCost
13800000
CY2021 us-gaap Lease Cost
LeaseCost
10900000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
12400000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
9400000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
10300000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16554000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16899000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
17263000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
14223000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
6590000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
27924000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
99453000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
20807000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
78646000
CY2023Q4 us-gaap Recorded Unconditional Purchase Obligation
RecordedUnconditionalPurchaseObligation
94533000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
6096000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
934000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
119581000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4550000
CY2023Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
55
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
278300000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
79200000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
287500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
287500000
CY2023Q4 ntra Debt Instrument Unamortized Debt Discount And Debt Issuance Cost
DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost
4555000
CY2022Q4 ntra Debt Instrument Unamortized Debt Discount And Debt Issuance Cost
DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost
5847000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
282945000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
281653000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235800000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13144500
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
35
CY2022Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
500000
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
433200000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5175000
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
113
CY2021Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
400000
CY2021Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
551200000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-91251000
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-114832000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-98931000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-13492000
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0310
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-21676000
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0396
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-29206000
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0620
CY2023 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
10837000
CY2023 ntra Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.0249
CY2022 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7024000
CY2022 ntra Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.0128
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
9193000
CY2021 ntra Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.0195
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-6422000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0148
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
3949000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.0072
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-46128000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.0979
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-106000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.0002
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
332000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0006
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
167000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0004
CY2023 ntra Income Tax Reconciliation Nondeductible Officers Compensation
IncomeTaxReconciliationNondeductibleOfficersCompensation
8651000
CY2023 ntra Effective Income Tax Reconciliation Nondeductible Officers Compensation
EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation
-0.0199
CY2022 ntra Income Tax Reconciliation Nondeductible Officers Compensation
IncomeTaxReconciliationNondeductibleOfficersCompensation
4883000
CY2022 ntra Effective Income Tax Reconciliation Nondeductible Officers Compensation
EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation
-0.0089
CY2021 ntra Income Tax Reconciliation Nondeductible Officers Compensation
IncomeTaxReconciliationNondeductibleOfficersCompensation
24387000
CY2021 ntra Effective Income Tax Reconciliation Nondeductible Officers Compensation
EffectiveIncomeTaxReconciliationNondeductibleOfficersCompensation
-0.0518
CY2023 ntra Income Tax Reconciliation Acquisition Costs
IncomeTaxReconciliationAcquisitionCosts
563000
CY2023 ntra Effective Income Tax Reconciliation Acquisition Costs
EffectiveIncomeTaxReconciliationAcquisitionCosts
-0.0013
CY2022 ntra Income Tax Reconciliation Acquisition Costs
IncomeTaxReconciliationAcquisitionCosts
3226000
CY2022 ntra Effective Income Tax Reconciliation Acquisition Costs
EffectiveIncomeTaxReconciliationAcquisitionCosts
-0.0059
CY2021 ntra Income Tax Reconciliation Acquisition Costs
IncomeTaxReconciliationAcquisitionCosts
8901000
CY2021 ntra Effective Income Tax Reconciliation Acquisition Costs
EffectiveIncomeTaxReconciliationAcquisitionCosts
-0.0189
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
-3397000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.0079
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
1964000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0036
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Other
IncomeTaxReconciliationNondeductibleExpenseOther
344000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.0005
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
116562000
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2682
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
130156000
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2380
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
150277000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3190
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
271000
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0006
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
978000
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0018
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
618000
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0013
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000.0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
399287000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
358109000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
67035000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
52319000
CY2023Q4 ntra Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
95923000
CY2022Q4 ntra Deferred Tax Assets Capitalized Research Costs
DeferredTaxAssetsCapitalizedResearchCosts
59128000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
34898000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
22781000
CY2023Q4 ntra Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
19339000
CY2022Q4 ntra Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
21000000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
29005000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
23814000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9449000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
9162000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
654936000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
546313000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
639510000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
526235000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
15426000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
20078000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1524000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1219000
CY2023Q4 ntra Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
13902000
CY2022Q4 ntra Deferred Tax Liabilities Right Of Use Lease Assets
DeferredTaxLiabilitiesRightOfUseLeaseAssets
18859000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
15426000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
20078000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
639500000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
639500000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
526200000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23844000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17514000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11500000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7034000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6301000
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6017000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
34000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
29000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
3000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
30912000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23844000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17514000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
30900000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23800000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17500000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22248000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19998000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17683000

Files In Submission

Name View Source Status
0001558370-24-002083-index-headers.html Edgar Link pending
0001558370-24-002083-index.html Edgar Link pending
0001558370-24-002083.txt Edgar Link pending
0001558370-24-002083-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20231231.xsd Edgar Link pending
ntra-20231231x10k.htm Edgar Link pending
ntra-20231231x10k006.jpg Edgar Link pending
ntra-20231231xex10d28.htm Edgar Link pending
ntra-20231231xex23d1.htm Edgar Link pending
ntra-20231231xex31d1.htm Edgar Link pending
ntra-20231231xex31d2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ntra-20231231x10k_htm.xml Edgar Link completed
ntra-20231231xex32d1.htm Edgar Link pending
ntra-20231231xex32d2.htm Edgar Link pending
ntra-20231231xex97d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
ntra-20231231_def.xml Edgar Link unprocessable
ntra-20231231_lab.xml Edgar Link unprocessable
ntra-20231231_pre.xml Edgar Link unprocessable
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ntra-20231231_cal.xml Edgar Link unprocessable